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Abstract:  
The objective of the study is to develop a stable lyophilized formulation of Zoledronic acid for injection for 
better stability and for long term storage.  The lyophilized product of all the formulations (F1- F6) prepared 
were an appearance of white to white Lyophilized cake. mannitol was used with water for injection . The filled 
vials were loaded into lyophilizer and lyophilized them as per cycle. Different composition of additives was used 
and the different pH concentrations of 5.7 to 6.7 were adjusted with sodium citrate were tried to formulate the 
formulation. The pH of all the formulations is in the range of 5.4-6.5. The related substances in formulations not 
exceeded the limit of 0.5%. The assay values of formulations (F1-F6) were in the range of 92% – 104 %. The 
formulations (F1- F6) show a water content range of 0.93% to 1.6 %. The results concluded that the 
formulation F4 is the optimized and the best formulation. Zoledronic acid was developed as lyophilised 
formulation for better stability. The obtained results suggested that a stable formulation for drug Zoledronic 
acid was developed which was comparable to reference listed product. 
Keywords: Lyophilisation, mannitol, Zoledronic acid. 
Corresponding Author:  
Rajesh akki, 
Department of Pharmaceutics 
Hindu college of Pharmacy, 
Guntur-522 002 
Andhra Pradesh 
Phone: +91 9908451213 
E.mail: rajuph111@gmail.com 
 
Please cite this article in press as Rajesh akki et al, Development, Evaluation and Stability of Zoledronic Acid 
I.V Injection by Lyophilization Technique, Indo Am. J. P. Sci, 2017; 4(07). 
 
 
 
 
 
 
 
 
QR code 
 
 
IAJPS 2017, 4 (07), 2042-2046                      Rajesh Akki et al                     ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 2043 
INTRODUCTION: 
Zoledronic acid is an nitrogen containing 
bisphosphonates and, like the other molecules of 
this class, binds to hydroxyapatite in the bone 
mineral matrix and strongly inhibits bone 
resorption. The ability of bisphosphonates to persist 
in bone matrix and to reduce osteoclast activity 
depends on their affinity for the bone matrix and 
potency of the inhibition of farnesyl 
pyrophosphate[1]. Zoledronic acid has the highest 
affinity for bone, followed by alendronate, 
ibandronate, risedronate, etidronate, and clodronate 
and it also alters mineral-surface properties, 
allowing greater adsorption. These properties are 
believed to contribute to its prolonged action [2]. 
The bioavailability of the BPs is very low when 
they are administered orally, but this problem is 
avoided by intravenous administration, such as 
with the yearly formulation of zoledronic acid. 
Orally administered BPs have shown 
approximately 1% bioavailability, whereas 
intravenous formulations have shown 100% 
bioavailability. Like the other BPs, zoledronic acid 
is eliminated rapidly in the urine, and studies of its 
endogenous metabolism have shown that it does 
not inhibit human cytochrome activity in vitro, in 
particular the p450 enzyme, or undergo 
biotransformation in vivo, indicating that it is not 
extensively metabolized[3-5]. After a single 
intravenous dose of zoledronate, bone turnover 
marker reduction reaches up to 80% after 1 month 
and persists over the following 12 months[6-8]. 
This is due to the high potency and affinity of 
zoledronic acid for hydroxyapatite and the 100% 
bioavailability afforded by the intravenous 
infusion[9-10]. Zoledronic acid is 1-hydroxy-2-
(1H-imidazole-1-yl) ethane-1,1-
diyl]bis(phosphonicacid). Molecular formula of 
Zoledronic acid is C18 H24 N2 
. Injections are sterile solutions, emulsions or 
suspensions. These are prepared by dissolving, 
emulsifying or suspending active substances and 
excipients in water, in non-aqueous vehicle or 
mixture of both. Injections are clear, free from 
particles and emulsions do not show any phase 
separation. Freeze-drying, or lyophilization, is in 
simple terms a dehydration technique. The aspect 
of the freeze-drying process that makes it different 
from other dehydration techniques is that 
dehydration takes place while the product is in a 
frozen state under a vacuum. These conditions 
stabilize the product, minimizing the effects of 
oxidation and other degradation processes. Freeze-
drying has become an accepted method of 
processing heat sensitive products that require long 
term storage at temperatures above freezing. 
Freeze-drying works by freezing the material and 
then reducing the surrounding pressure and adding 
enough heat to allow the frozen water in the 
material to sublime directly from the solid phase to 
gas. Lyophilization or freeze-drying is often used to 
stabilize various pharmaceutical products, 
including virus vaccines, protein and peptide 
formulations, and liposome and small chemical 
drugs susceptible to physical and chemical 
degradation when stored as a ready-to-use solution. 
The lyophilization process consists of three stages 
they are Freezing (Solidification), Primary drying 
(Ice sublimation), Secondary Drying (Desorption of 
Unfrozen Water). Secondary drying parameters are 
based on the quantity and nature of the residual 
water in the product, the absorption, adsorption and 
desorption processes. Tigecycline in liquid 
injection was found to be unstable. The major 
objective of this experiment is to formulate the 
tigecycline injection by lyophillization technique 
for better stability and for long term storage.In 
lyophilized preparations, Mannitol is used as a 
carrier to produce a stiff, homogeneous cake that 
improves the appearance of the lyophilized plug in 
a vial [11-12]. 
 
MATERIALS AND METHODS 
Zoledronic acid procured from Natco Pharma Ltd, 
Hyderabad; Mannitol and Sodium citrate were 
supplied by Roquette, Germany. 
Methods: Zoledronic acid drug is an active 
ingredient, Mannitol were used as lyophilization 
aid, water for injection as a vehicle for solubility 
and concentrated Sodium citrate for pH adjustment 
 
 
Table 1: Formulation of Zoledronic acid Injection 
S.No Ingredients F1 F2 F3 F4 F5 F6 
1 
Zoledronic 
acid drug 
1gm 1gm 1gm 1gm 1gm 1gm 
2 Mannitol 50gm 57.5gm 56.5gm 55gm 55.5gm 57gm 
3 Sodium citrate 5gm 5.5gm 6.5gm 6gm 5gm 7gm 
4 
Water For 
Injection 
q.s to 500 
ml 
q.s to 500 
ml 
q.s to 500 
ml 
q.s to 500 
ml 
q.s to 500 
ml 
q.s to 500 
ml 
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Method of Preparation: 
WFI is freshly collected at 700C to 800C in 1 liter 
glass vessel then cool to 300C to 350C.1gm of 
Zoledronic acid drug was slowly added to the 
above WFI with continuous stirring. mannitol was 
added to the above solution with continuous 
stirring for 8 min. check clarity of solution for 
homogeneous mixing.Make up the volume to 500 
ml with WFI. Adjust the volume on wt/ml. 
Withdraw 5 ml sample for analysis as per current 
approved in process specification ASSAY- (1.96 - 
2.04) mg/ml WEIGHT/ml – 1.04 g/ml sodium 
citrate was added to the above solution and checks 
the pH of solution 5.7 to 6.7 record pH. The 
solution is filtered through 0.22µ PVDF membrane 
filter (BACTERIA RETENTIVE FILTER).2ml 
solution is filled into 6ml tubular Type-1 flint vials 
are half stoppered with 13mm lyophilized stoppers. 
The filled vials are located into the lyophilizer and 
the vials are lyophilized as per cycle (Set the shelf 
temperature, 55, prior to cycle starts). The samples 
are collected at the end of lyophilization cycle. The 
samples are withdrawn under the nitrogen 
atmospheric conditions after the atmospheric 
pressure is reached these vials are stoppered and 
sealed. The vials are unloaded from the lyophilizer 
and sealed by using flip of aluminium seals.The 
vials are stored at room temperature. 
Assay: HPLC equipped with UV detector.Column: 
inersill-3v (250*4.6mm) Flow rate: 0.8ml/min 
Wavelength: 215nm Column temp: 300C Injection 
volume: 100µL Run time: 30 min for peak 
identification and 60 min for diluent, placebo and 
sample preparation. 
 
Stability studies: Accelerated stability study was 
conducted for the optimised batch under various 
temperature and humidity conditions. The water 
content, assay and pH were determined and 
compared with standard conditions. 
 
RESULTS AND DISCUSSION: 
Table 2:  Determination of solubility of 
Zoledronic acid drug 
No of Trails Description  pH Assay  
Formula 1 Turbid solution 6.62 97.5% 
Formula 2 Turbid solution 6.65 94.5% 
Formula 3 Turbid solution 6.76 103.56% 
Formula 4 Clear solution 6.56 100.5% 
Formula 5 Turbid solution 6.80 95.8% 
Formula 6 Clear solution 6.75 104.4% 
 
Zoledronic acid drug is freely soluble in NaOH and 
sparingly soluble in water. Bisphosphonate drug is 
poorly soluble in methanol and ethanol. From 
experimental data, it is proved that Zoledronic acid 
drug is sparingly soluble in NaOH and very slightly 
soluble at different concentrations of sodium citrate 
and mannitol. The pH and assay of Zoledronic acid 
drug in different concentrations of sodium citrate 
and mannitol are represented in the above table. 
F1 is performed with the drug Zoledronic acid 
drug, mannitol, sodium citrate and water for 
injection. As the WFI content in the formulation is 
more, the moisture content in the lyophilized 
product is more so the assay of the finished product 
is less. So the next formulation is planed with 
different concentration of sodium citrate and 
mannitol. In F2 formulation the solubility of the 
drug in formula 2 is less but more compared to 
formula 1. So the assay is increased compared to 
F1. The moisture content is decreased as the 
percentage of WFI decreased in F2 compared to 
F1. So the further formulation is planned with 
different concentration of sodium citrate and 
mannitol. In F3 formulation the solubility of the 
drug is more compared to the solubility in F2. So 
there is an increase in the assay of formulation 
compared to F1 and F2. The percentage of WFI 
added in the formulation is less when compared to 
F1 and F2. So the water content in the final product 
was also low. To get even better results trails are 
planned with the increased different concentration 
of sodium citrate and mannitol. In F4 formulation, 
the drug Zoledronic acid drug gets completely 
solubilized in different concentrations of sodium 
citrate and mannitol. So there is a 100% assay for 
the final lyophilized product. For a lyophilized 
powder the related substance and water content 
plays critical role. The particulate count is also less 
compared with other formulations to reconfirming 
the above statement, further formulation is planned 
with increased different concentration of sodium 
citrate and mannitol. In F5 formulation, the drug 
Zoledronic acid drug completely soluble in 
different concentrations of sodium citrate and 
mannitol. The assay is increased because of 
decreasing hydrolysis as the water percentage has 
decreased in the formulation. The percentage of 
water content of final product has also decreased. 
In F6 formulation, the drug Zoledronic acid drug is 
completely soluble in different concentrations of 
sodium citrate and mannitol. This has resulted in an 
increase in the assay of the formulation and the 
water content of the lyophilized vials is also 
decreased. 
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                         Table 3:  Evaluation Test for Zoledronic Injection 
 
S.No Test F1 F2 F3 F4 F5 F6 
1 Description 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
2 pH 5.4 6.5 6.28 6.37 6.47 6.39 
3 
Related 
substance 
0.6% 0.4% 0.30% 0.3% 0.5% 0.25% 
4 Assay 92.4% 94.4% 96.3% 100.1% 104.3% 101.2% 
5 
Water 
content 
1.201 0.935 1.631 0.937 1.103 1.199 
6 
Sub visible 
particle 
≥10µm 
≥25µm 
 
1413.0 
19.8 
 
3637.8 
31.8 
 
2604.0 
75.0 
 
1937.8 
28 
 
1195.6 
24 
 
4252.8 
72.0 
 
 
Stability studies: 
The accelerated stability studies were carried out as 
per ICH guidelines at 
40⁰c±2⁰c/75%RH±5%RH.The optimized 
lyophilized formulation under stability studies were 
analyzed at a time interval of one month up to three 
months. The formulations were analyzed for all the 
evaluation parameters such as color of the product, 
reconstitution time, pH, assay, particulate matter. In 
the 1st month stability analysis, the color of the 
product was same as the initial product and no 
color change was observed. The entire product was 
reconstituted with 5ml of special diluent and the 
reconstitution time noted was 0.02secs. The pH of 
all the solution was found to be 6.24 and no 
significance difference was observed compared to 
initial product. Assay was carried out by HPLC and 
was found to be within the I.P limits The 
particulate matters were found to be 1326(≤10µm) 
and 23(≤25µm). These data were within I.P 
specification and hence, the product was stable 
after one month. In second month and third month 
stability analysis, the appearance of the product 
was same as the initial product and no color change 
was observed. All the evaluation parameters were 
found to be within limits as given. From the above 
result it was concluded the product was stable 
under accelerated stability study condition which 
qualifies batch-4 to have an expected shelf-life of 
2years. From the above discussions, it is evident 
that finally batch-4 could be optimized as the target 
lyophilized product of Zoledronic acid IV injection 
with better stability than marketed formulations. 
Hence an objective of developing a stable and 
extended shelf-life lyophilized Zoledronic acid IV 
injection was achieved. 
 
 
Fig1: Stability studies of F4 at 400C± 20C/60%RH± 5%RH 
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Table 4: Comparative Evaluation Results of all the Formulations 
Evaluation 
Parameters 
Innovator F1 F2 F3 F4 F5 F6 
Description 
 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
White 
lyophilized 
cake 
pH 5.32 5.4 6.5 6.28 6.37 6.47 6.39 
Related Substance 0.5% 0.6% 0.4% 0.3% 0.3% 0.5% 0.25% 
Assay 108.5% 92.4% 94.4% 96.3% 100.1% 104.3% 101.2% 
Water Content 2.5 1.201 0.935 1.631 0.937 1.103 1.199 
Sub-Visible 
Particle 
≥10µm 
≥25µm 
 
 
6000 
600 
 
 
1413 
19 
 
 
3637 
31 
 
 
2604 
75 
 
 
781 
10 
 
 
1195 
24 
 
 
4252 
72 
The results of all the 6 formulations were tabulated and concluded that the formulation F4 was the optimized 
formulation with the best evaluation parameters. 
Table 5: Comparative analytical profile among reference listed drug Zoledronic acid (90hr and 58hrs) and 
Zoledronic acid drug for injection F4. 
Evaluation parameters Reference listed (RLD) at 
90hr 
Reference listed (RLD) at 
58hr 
Formulation F4 at 40hr 
Description White lyophilized cake White lyophilized cake White lyophilized cake 
pH 6.87 6.95 6.37 
Related substance 0.48% 0.54% 0.3% 
Assay 97.5% 98.4% 100.1% 
Water content 1.40 1.45 0.937 
Sub-visible particle 
≥10µm 
≥25µm 
 
1035 
15 
 
1565 
25 
 
781 
10 
 
 CONCLUSION: 
From the above results it is concluded that the 
formulation F4 is optimized and the best 
formulation. The evaluation parameters like assay, 
related substance, particulate matter and water 
content for the formulation F4 are within the limits. 
The comparative results between the RLD and 
Zoledronic acid drug F4 formulation have shown 
that the RLD which are comparatively less in 
efficiency than the Zoledronic acid drug for 
injection F4 formulation which was carried out 
using 40hrs lyophilization cycle period. From the 
accelerated stability studies it is concluded that the 
Zoledronic acid drug for injection should be stored 
at room temperature (250C) and should not be 
subjected to high temperature. 
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